We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Nadia
Haynes
Nadia.haynes@nelft.nhs.uk
joanna
Moncrieff
joanna.moncrieff@nelft.nhs.uk
Schizophrenia, schizotypal and delusional disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Antipsychotics are a medication given to people with schizophrenia and similar conditions. Schizophrenia is a serious mental health condition affecting 1% of the population. It causes a range of psychological symptoms involving a person's thoughts, feelings and behaviour. Antipsychotics can reduce the symptoms of schizophrenia in the short-term, but we do not know if they are useful in the long-term. This is important because most people take antipsychotics for many years. Antipsychotics can also have unpleasant and dangerous side-effects.
Past research has shown that some people who reduce or stop antipsychotic medication may do better in the long-run compared to people who keep taking it. We previously conducted a randomised controlled trial exploring what happens to people who reduce and come off their antipsychotic medication gradually with support from their doctor, compared to people who stay on it. This is called the RADAR study.
In the current study, we want to understand how things turn out in the long-run. In order to do this, we want to follow-up the people enrolled in the RADAR study a few years later to see how they are doing in the long-run. We enrolled 253 people in the RADAR study at the start. The proposed research will involve conducting a follow-up interview with as many of these participants as possible. The interview will take place between 4 and 7 years after people started the RADAR trial. Doing this long-term follow-up is important because some evidence suggests that people who reduce or stop their medication may have improved outcomes but the benefits only start after 3 to 4 years. In the follow-up interview, we will assess people's mental health, social functioning, quality of life and medication use and we will also obtain information from their medical records about any admissions to hospital.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Validation of outcome measures;
You can take part if:
You may not be able to take part if:
Below are the exclusion for the original trial and all participants who entered the trial will be eligible for follow-up unless they have withdrawn or passed away: EXCLUSION CRITERIA 1. Participant lacks capacity to consent to the trial. 2. Participant has insufficient command of spoken English to understand trial procedures 3. Participant subject to section 37/41 of the Mental Health Act (MHA) or a Community Treatment Order (CTO) that includes a requirement to take antipsychotic medication 4. Clinician considers there will be a serious risk of harm to self or others 5. Participant has been admitted to hospital or had treatment from the Home Treatment or Crisis Team within the last month 6. Females who have a confirmed pregnancy 7. Females who are breast-feeding 8. Involvement in another IMP trial 9. No contraindications to continuing on antipsychotic medication
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by NORTH EAST LONDON NHS FOUNDATION TRUST and funded by NIHR Central Commissioning Facility (CCF) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 53299
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
